MK 0941

Drug Profile

MK 0941

Alternative Names: MK-0941

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 24 Sep 2010 Efficacy and safety data from three phase II trials in Type-2 diabetes mellitus presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD-2010)
  • 24 Feb 2010 Merck completes two multinational phase II trials (NCT00824616 and NCT00792935) in Type-2 diabetes mellitus
  • 17 Nov 2008 Phase-II clinical trials in Type-2 diabetes mellitus in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top